DNLI R&D to Revenue
Denali Therapeutics Inc · R&D to Revenue
DNLI R&D to Revenue
Latest reported2691.98%period ending
DNLI Quarterly R&D/Revenue (0.00% → 2691.98%)
Latest values, visible window
High-resolution chart · PNG
DNLI r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 2,691.9811% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 7,082.6361% | |
| 33.1562% | |
| 366.569% | |
| 895.76% | |
| 2,466.5917% | |
| 176.7092% | |
| 204.3093% | |
| 542.4005% | |
| 1,354.0019% | |
| 286.4597% | |
| 759.9016% | |
| 17.2792% | |
| 571.7449% | |
| 909.0474% | |
| 1,415.5383% | |
| 1,103.4033% | |
| 386.2393% | |
| 1,236.2163% | |
| 889.4887% | |
| 31.7555% | |
| 2,537.3222% | |
| 3,163.4709% | |
| 3,247.8939% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |